Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Adaptimmune Ther ADR (ADAP)

Adaptimmune Ther ADR (ADAP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Adaptimmune Ther ADR 60 JUBILEE AVENUE MILTON PARK ABINGDON X0 OX14 4RX GBR

www.adaptimmune.com Employees: 506 P: 44-12-3543-0000

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.

Key Statistics

Overview:

Market Capitalization, $K 14,551
Enterprise Value, $K -26,349
Shares Outstanding, K 265,052
Float, K 232,080
% Float 87.56%
Short Interest, K 31,377
Days to Cover 1.00
Short Volume Ratio 0.43
% of Insider Shareholders 12.44%
% of Institutional Shareholders 31.37%

Financials:

Annual Sales, $ 178,030 K
Annual Net Income, $ -70,810 K
Last Quarter Sales, $ 13,680 K
Last Quarter Net Income, $ -30,340 K
EBIT, $ -153,750 K
EBITDA, $ -142,520 K

Growth:

1-Year Return -92.56%
3-Year Return -96.57%
5-Year Return -98.95%
5-Year Revenue Growth 15,795.54%
5-Year Earnings Growth 81.06%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.11 on 08/13/25
Next Earnings Date 11/12/25
Earnings Per Share ttm -0.62
EPS Growth vs. Prev Qtr 38.89%
EPS Growth vs. Prev Year -140.74%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

ADAP Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -75.83%
Profit Margin % -39.77%
Debt/Equity -0.36
Price/Sales 0.10
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.27
Interest Coverage -19.07
60-Month Beta 2.49
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar